Lannett Company Inc. is recalling 14,448 bottles of Oxybutynin Chloride Extended-Release Tablets (10 mg), a prescription medication used to treat overactive bladder. This recall was initiated because the tablets failed dissolution specifications, meaning the drug may not release properly into the body. This could result in the medication being less effective at managing symptoms or potentially releasing too much medicine at once. These 100-count bottles were distributed nationwide, including to Puerto Rico.
The failure to meet dissolution standards means the medication may not dissolve at the correct rate, which can lead to inconsistent blood levels of the drug and a potential failure to control bladder symptoms.
Contact healthcare provider and return product
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.